Invention Grant
- Patent Title: Inhibitors of AKT activity
- Patent Title (中): AKT活性抑制剂
-
Application No.: US13255757Application Date: 2010-03-03
-
Publication No.: US08168652B2Publication Date: 2012-05-01
- Inventor: Philip E. Sanderson , Mark E. Layton , Kevin J. Rodzinak
- Applicant: Philip E. Sanderson , Mark E. Layton , Kevin J. Rodzinak
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Matthew A. Leff; Yong Zhao; David A. Muthard
- International Application: PCT/US2010/025990 WO 20100303
- International Announcement: WO2010/104705 WO 20100916
- Main IPC: A61K31/44
- IPC: A61K31/44 ; C07D471/02
Abstract:
The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
Public/Granted literature
- US20110319443A1 INHIBITORS OF AKT ACTIVITY Public/Granted day:2011-12-29
Information query
